<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593368</url>
  </required_header>
  <id_info>
    <org_study_id>NCPHOI-2019-04</org_study_id>
    <nct_id>NCT04593368</nct_id>
  </id_info>
  <brief_title>Fecal Microbiome Transplantation (FMT) in Pediatric Patients Colonized With Antibiotic-resistant Pathogens Before Hematopoietic Stem Cell Transplantation (HSCT)</brief_title>
  <acronym>FMT-HSCT</acronym>
  <official_title>Prospective Non-randomized Phase II Clinical Trial of Safety and Efficacy of Fecal Microbiome Transplantation for Pediatric Patients 3-18 Years Old With Confirmed Colonization With Antibiotic-resistant Bacterias and Indication for Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      a clinical trial designed to prospectively assess the safety and effectiveness of fecal&#xD;
      microbiota transplantation (FMT) prior to allogeneic hematopoietic stem-cell translation&#xD;
      (HSCT) in patients contaminated with antibiotic-resistant pathogens (ARP)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator's question is whether FMT decontaminates ARP and as a result, decreases the&#xD;
      risk of severe infection which leads to transplant-related morbidity and mortality after&#xD;
      HSCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>7 days after FMT</time_frame>
    <description>frequency of decolonization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>frequency of SAEs</measure>
    <time_frame>1 month after FMT</time_frame>
    <description>frequency of SAEs due to FMT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decolonization</measure>
    <time_frame>30 days after FMT</time_frame>
    <description>frequency of decolonization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute gut GVHD CI</measure>
    <time_frame>100 days after HSCT</time_frame>
    <description>CI of gut GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity frequency</measure>
    <time_frame>7 days after FMT</time_frame>
    <description>frequency of severe toxicity (3-4 grade according to the CTCAE ver 5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteremia</measure>
    <time_frame>100 days after FMT</time_frame>
    <description>frequency of bacteremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translocation</measure>
    <time_frame>1 year</time_frame>
    <description>frequency of translocation of pathogens from gut</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Antibiotic Resistant Strain</condition>
  <arm_group>
    <arm_group_label>FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FMT</intervention_name>
    <description>oral dosing of fecal microbiome from allogeneic donor, 0.5-2 g/kg of recipients weight</description>
    <arm_group_label>FMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recipients&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. detection by microbiology culture in any localization species of:&#xD;
&#xD;
               -  Pseudomonas aeruginosa&#xD;
&#xD;
               -  Clostridium difficile&#xD;
&#xD;
               -  Vancomycin-resistant Enterococcus&#xD;
&#xD;
               -  Streptococcus viridans&#xD;
&#xD;
               -  ESBL Enterobacteriaceae, including Escherichia coli and Klebsiella pneumoniae&#xD;
&#xD;
               -  Stenotrophomonas maltophilia&#xD;
&#xD;
               -  Acinetobacter&#xD;
&#xD;
               -  Methicillin-resistant Staphylococcus aureus&#xD;
&#xD;
          2. Indications for allo-HSCT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. indications for therapy with antibiotics for the next 7 days after FMT&#xD;
&#xD;
          2. Nonstable condition during 1 week before FMT&#xD;
&#xD;
          3. Therapy with antibiotics less than 48 hours before FMT&#xD;
&#xD;
          4. Age less than 3 years&#xD;
&#xD;
          5. Neutrophils count &lt; 0,5 K/mcL at FMT day and\or predicted decrease during 2 days after&#xD;
             Donors (healthy volunteers)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 3-50 years old&#xD;
&#xD;
          2. Donor choosing order in the absence of contraindications:&#xD;
&#xD;
        1) HLA-match/mismatch HSCT family donor; 2) Closest family relative with whom the recipient&#xD;
        lives; 3) Unrelated healthy volunteer from the FRCC PCM bank of frozen transplants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presens of:&#xD;
&#xD;
               -  ESBL Esherihia coli&#xD;
&#xD;
               -  Klebsiella pneumoniae&#xD;
&#xD;
               -  Pseudomonas aeruginosa&#xD;
&#xD;
               -  Clostridium difficile&#xD;
&#xD;
               -  MRSA&#xD;
&#xD;
               -  VRE&#xD;
&#xD;
               -  Streptococcus viridans&#xD;
&#xD;
               -  ESBL Enterobacteriaceae&#xD;
&#xD;
               -  Stenotrophomonas maltophilia&#xD;
&#xD;
               -  Acinetobacter in feces by microbiology culture assay&#xD;
&#xD;
          2. Therapy with antibiotics less than 3 months before donation&#xD;
&#xD;
          3. Any infection disease revealed during the screening&#xD;
&#xD;
          4. Latent period of infection disease according to the questionnaire&#xD;
&#xD;
          5. Gut disease&#xD;
&#xD;
          6. Longitudinal treatment with drugs&#xD;
&#xD;
          7. Any diet for 3 months before donation.&#xD;
&#xD;
          8. Obesity (BMI â‰¥ 30).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhanna Shekhovtsova</last_name>
    <phone>84956647078</phone>
    <phone_ext>5553</phone_ext>
    <email>zhanna.shekhovtsova@fccho-moscow.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhanna Shekhovtsova</last_name>
      <phone>84956647078</phone>
      <phone_ext>5553</phone_ext>
      <email>zhanna.shekhovtsova@fccho-moscow.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal Research &amp; Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Elena Zhgun</last_name>
      <phone>84992464438</phone>
      <email>al.androva@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Oleg GOLOSHCHAPOV</last_name>
      <email>Golocht@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>hematopoetic stem-cell transplantation</keyword>
  <keyword>FMT</keyword>
  <keyword>microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sprains and Strains</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

